AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03603678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2253651
Description: 100 µg (500 µg/ml \* 200 µl) BAY2253651 intranasally
Study NCT03077776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
Study NCT03077776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (optional)
Description: \[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
Study NCT03077776 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy (metastatic)
Description: Biopsy of metastatic site to be performed at the time of relapse
Study NCT03603678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo dosing
Study NCT00961909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
Study NCT00961909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5095932
Description: dose titration to target dose, sc once weekly for 6 weeks
Study NCT00961909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: stable dose
Study NCT00961909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: stable dose
Study NCT03946527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
Study NCT02019069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine-daunorubicin CPX-351
Description: Given IV
Study NCT04032938 — intervention group
Intervention type: PROCEDURE
Intervention: extracorporeal circulation during cardiac surgery
Description: We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
Study NCT00539474 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radio guided occult lesion localisation
Description: ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
Study NCT00539474 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio guided occult lesion localisation
Description: ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
Study NCT00961909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly for 4 weeks
Study NCT03018483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable PSV
Description: Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.~In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician.
Study NCT03018483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PSV
Description: Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.
Study NCT03018483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated PSV
Description: Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
Study NCT01374386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Participants will have access to Exergaming equipment (video games that require physical activity)
Study NCT03018483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NAVA
Description: NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
Study NCT01709032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox and deferiprone
Study NCT00048958 — intervention group
Intervention type: GENETIC
Intervention: cytogenetic analysis
Study NCT03708835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional care model
Description: In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
Study NCT03979703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 week yoga class
Description: Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
Study NCT01629225 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Candesartan
Description: To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Study NCT04458480 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Fast Inpatient Rehabilitation
Description: Routine inpatient rehabilitation protocol, administered by licensed Physical Therapist, duration period of 1.5h-2h each time, 2 times for weekdays and 1 time for weekends, totally lasting for 1 week, are applied to the exposed group. After the fast inpatient rehabilitation for 1 week, the patients can get discharged if reaching to the rehabilitation goals of symptoms of pain and swell reduced, knee flexion ≥ 90° and knee extension ≥ 0°, quadriceps femurs and hamstrings muscle strength enhanced, recovery to aided standing and walking, and acquiring of rehabilitation training methods.
Study NCT02709902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/BP gel, 0.3%/2.5%
Description: Gel
Study NCT02709902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPIDUO® FORTE
Description: Gel
Study NCT02709902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel
Study NCT03416777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meat-based diet
Description: Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
Study NCT03416777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat-based diet supplemented with alpha-tocopherol (MBD-T)
Description: Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
Study NCT03524209 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous instrumentation of the thoracolumbar spine
Description: The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
Study NCT03524209 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brace
Description: Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
Study NCT03491592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Activity Intervention
Description: Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
Study NCT03491592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original Physical Activity Intervention
Description: Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
Study NCT03989505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood-draw for biomarker analyses
Description: Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
Study NCT01256632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03416777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pesco-vegetarian diet
Description: Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
Study NCT02123979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupro® transdermal patch/placebo
Description: 8mg transdermal patch Neupro® transdermal patch/placebo
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT02123979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neupro® transdermal patch/placebo
Description: 8mg transdermal patch Neupro® transdermal patch/placebo
Study NCT03929393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Movement
Description: The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally
Study NCT03587597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique
Description: socket shield technique with immediate temporization
Study NCT03587597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional immediate implant placement with immediate temporization
Description: conventional immediate implant placement with immediate temporization
Study NCT00591799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Jarvik 2000 Ventricular Assist System
Description: Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
Study NCT02254824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xuezhikang
Description: Xuezhikang
Study NCT02254824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin
Study NCT02254824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Lifestyle modification
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given orally
Study NCT00499616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
Study NCT03929393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Keys to Health & Wellbeing
Description: This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
Study NCT00499616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy \& continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
Study NCT01722799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug elluting Balloon (DEB)
Description: Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
Study NCT01722799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug elluting coronary stent (DES)
Description: Percutaneous transluminal coronary angioplasty (PTCA) with stent
Study NCT01930578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with 0.9% normal saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
Study NCT04690426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-101
Description: Coxsackie Virus B vaccine
Study NCT04690426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03272152 — intervention group
Intervention type: GENETIC
Intervention: Genome-wide DNA methylation
Description: Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
Study NCT05945407 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Indication-extended Fertility-sparing Therapy
Description: Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions.
Study NCT05945407 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Indication-extended Fertility-sparing Therapy
Description: Patients will receive medroxyprogesterone acetate (FARLUTAL) 250-500mg/d or megestrol acetate (YiLiZhi) 160-320mg/d orally. If there is no response after 6 months of treatment, change the regimen to levonorgestrel intrauterine system (Mirena) and gonadotropin-releasing hormone agonist (Leuprorelin, Goserelin or Triptorelin) 3.75mg/28d injection subcutaneously. After complete remission, the same regimen will be used for consolidation treatment for another 1-3 months. Subsequently, if the patient has no intention of pregnancy, render maintenance treatment (Mirena, Progesterone, Dydrogesterone, or combined oral contraceptive). Otherwise, the patient will be encouraged to conceive either by an expectation for 3-6 months, or by assisted reproductive technology. Indications for stopping fertility-sparing therapy: 1) disease progression; 2) no response after 9 months of treatment; 3) repeated recurrence; 4) no longer require sparing fertility; 5) serious adverse reactions.
Study NCT01604772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO
Study NCT01604772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02052635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
Study NCT02052635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
Study NCT01571791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
Study NCT01571791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac-Lidocaine
Description: receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
Study NCT00817063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alitretinoin
Description: Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
Study NCT00817063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receive matching placebo for up to 24 weeks
Study NCT00651846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yasmin (DRSP 3mg/EE 0.03 mg)
Description: The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
Study NCT00651846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon (LNG 0.15 mg/EE 0.03 mg)
Description: The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
Study NCT00025337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01930578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with D5+ 0.45 saline
Description: An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design.
Study NCT03492177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selexipag (Uptravi)
Description: Film-coated tablets for oral administration